The efficacy and safety of novel anti-obesity therapies.

PAPAZAFIROPOULOU, A. K.; PAPANAS, N.; MELIDONIS, A.

Obesity is a chronic disease with a high prevalence in both developed and developing countries. Lifestyle interventions, such as restricting calorie consumption and increasing physical activity, continue to be the cornerstone of weight-reduction programs. Novel anti-obesity drug therapies are currently gaining in importance. These include lorcaserin (a selective serotonin agonist), phentermine/topiramate combination, naltrexone/bupropion combination (acting on the hypothalamus), and liraglutide, an established anti-diabetic agent which suppresses the appetite. This is a brief review of the evidence on the role of these anti-obesity drugs in the management of obesity.

Archives of Hellenic Medicine / Arheia Ellenikes Iatrikes, 2015, Vol 32, Issue 3, p295

1105-3992

Academic Journal